Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...
Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a weight-loss drug.
Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...
NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...
Tirzepatide has already been filed for approval ... related comorbidity suggests it could also be a potent rival to Novo Nordisk's obesity portfolio. Over 72 weeks, patients taking a weekly ...
We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
Novo Nordisk's (NVO) weight loss drug Wegovy ... Eli Lilly's (LLY) rival Zepbound (tirzepatide) does not yet have a CVD indication though the company is pursuing it. Data from the phase 3 SUMMIT ...
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback